Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Dosing in Congenital Acyanotic Heart Disease Surgery
NCT05103397Phase 4Unknown
- Sponsor
- Ain Shams University
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of methylprednisolone in congenital heart disease (CHD), sponsored by Ain Shams University. Status: unknown.
02
Drugs
methylprednisolone
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT05103397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103397.